Navepegritide
- Generic Name
- Navepegritide
A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.
Phase 2
Recruiting
- Conditions
- Achondroplasia
- Interventions
- Drug: Placebo for navepegritide
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Ascendis Pharma A/S
- Target Recruit Count
- 24
- Registration Number
- NCT06732895
- Locations
- 🇫🇷
Ascendis Investigational Site, Paris, France
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia
Phase 2
Recruiting
- Conditions
- Achondroplasia
- Interventions
- Drug: Placebo for Navepegritide
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Ascendis Pharma Growth Disorders A/S
- Target Recruit Count
- 72
- Registration Number
- NCT06079398
- Locations
- 🇬🇧
Ascendis Investigational Site, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath